New antidote liposome tested in healthy people for first time
NCT ID NCT07375498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new liposome-based antidote in 12 healthy adults aged 18-30. The goal is to check safety and how the body processes the drug, not to treat any disease. Participants must be in good health and avoid pregnancy during the study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Daniele Hamamoto
Campinas, São Paulo, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibody tame the Body's allergic alarm system?
- Fingerprint sweat could replace oral swabs for drug testing
- Wearable tech puts hormone health to the test
- Can a better hazmat suit keep first responders safer and more effective?
- Home video tracking may expose the gap between clinic walking and real-world walking after stroke
- Avocado at breakfast: a secret weapon for blood sugar and fullness?